An Act relative to newborn screenings for congenital cytomegalovirus
Massachusetts mandates newborn screening for congenital cytomegalovirus to enable early detection and treatment of infections affecting 1 in 200 newborns.
Massachusetts mandates newborn screening for congenital cytomegalovirus to enable early detection and treatment of infections affecting 1 in 200 newborns.
HD 4718 requires Massachusetts to add congenital cytomegalovirus (CMV) screening to the state's standard newborn screening panel. CMV is a common viral infection that can cause significant complications in newborns, including hearing loss, developmental delays, and vision problems. The bill mandates that all newborns receive testing for this condition as part of routine hospital screening procedures.
Congenital CMV affects approximately 1 in 200 newborns, making it one of the most common congenital infections, yet many cases go undetected without specific screening. Early detection enables prompt medical intervention—including antiviral treatment—that can substantially reduce hearing loss and other developmental disabilities. Currently, most U.S. states do not routinely screen for CMV, leaving affected infants at risk for preventable complications that could have lifelong educational and health implications.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.